GAMMA Investing LLC Has $414,000 Holdings in HCA Healthcare, Inc. (NYSE:HCA)

GAMMA Investing LLC raised its position in HCA Healthcare, Inc. (NYSE:HCA) by 18.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,290 shares of the company’s stock after purchasing an additional 204 shares during the quarter. GAMMA Investing LLC’s holdings in HCA Healthcare were worth $414,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IMS Capital Management acquired a new position in HCA Healthcare in the 1st quarter valued at approximately $207,000. Railway Pension Investments Ltd lifted its holdings in HCA Healthcare by 3.6% during the 1st quarter. Railway Pension Investments Ltd now owns 148,367 shares of the company’s stock worth $49,485,000 after buying an additional 5,100 shares during the period. DekaBank Deutsche Girozentrale raised its position in shares of HCA Healthcare by 45.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 96,506 shares of the company’s stock worth $31,920,000 after acquiring an additional 30,139 shares during the last quarter. Cetera Advisors LLC boosted its holdings in HCA Healthcare by 37.3% in the first quarter. Cetera Advisors LLC now owns 7,049 shares of the company’s stock valued at $2,351,000 after acquiring an additional 1,916 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in HCA Healthcare by 205.2% during the 1st quarter. Cetera Investment Advisers now owns 18,753 shares of the company’s stock worth $6,255,000 after purchasing an additional 12,608 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Michael S. Cuffe sold 1,600 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $309.00, for a total transaction of $494,400.00. Following the completion of the sale, the executive vice president now directly owns 34,124 shares of the company’s stock, valued at approximately $10,544,316. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Michael S. Cuffe sold 1,600 shares of HCA Healthcare stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $309.00, for a total value of $494,400.00. Following the completion of the sale, the executive vice president now owns 34,124 shares of the company’s stock, valued at approximately $10,544,316. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $360.20, for a total value of $1,440,800.00. Following the completion of the sale, the senior vice president now directly owns 40,449 shares of the company’s stock, valued at approximately $14,569,729.80. The disclosure for this sale can be found here. Insiders sold a total of 20,268 shares of company stock valued at $6,804,285 in the last ninety days. 1.60% of the stock is currently owned by insiders.

HCA Healthcare Stock Down 1.9 %

HCA traded down $6.76 during mid-day trading on Friday, reaching $356.36. 1,604,536 shares of the stock were exchanged, compared to its average volume of 1,536,892. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06. The company has a 50 day moving average price of $334.20 and a two-hundred day moving average price of $324.97. HCA Healthcare, Inc. has a 1 year low of $215.96 and a 1 year high of $369.41. The stock has a market capitalization of $91.97 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 1.39 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Tuesday, July 23rd. The company reported $5.50 EPS for the quarter, topping the consensus estimate of $4.97 by $0.53. The firm had revenue of $17.49 billion for the quarter, compared to analysts’ expectations of $17.05 billion. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $4.29 EPS. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 22.43 EPS for the current year.

HCA Healthcare Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 16th will be given a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Monday, September 16th. HCA Healthcare’s dividend payout ratio is presently 13.16%.

Wall Street Analyst Weigh In

HCA has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft lifted their target price on shares of HCA Healthcare from $359.00 to $375.00 and gave the stock a “buy” rating in a research note on Friday, June 28th. Barclays upped their target price on HCA Healthcare from $376.00 to $396.00 and gave the company an “overweight” rating in a research report on Wednesday, July 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $335.00 price target on shares of HCA Healthcare in a research note on Wednesday, July 24th. Robert W. Baird began coverage on shares of HCA Healthcare in a research note on Thursday, May 30th. They issued an “outperform” rating and a $396.00 price objective for the company. Finally, Oppenheimer raised their price target on shares of HCA Healthcare from $345.00 to $390.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $344.06.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.